Meridian Bioscience Inc. (NASDAQ:VIVO) Receives Average Recommendation of “Hold” from Brokerages

Shares of Meridian Bioscience Inc. (NASDAQ:VIVO) have been assigned an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $12.00.

VIVO has been the topic of a number of recent analyst reports. BidaskClub lowered shares of Meridian Bioscience from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Canaccord Genuity raised their target price on shares of Meridian Bioscience from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Wednesday, May 3rd. Finally, Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Saturday, April 29th.

Meridian Bioscience (NASDAQ VIVO) opened at 13.45 on Friday. Meridian Bioscience has a one year low of $10.75 and a one year high of $19.85. The stock’s 50 day moving average is $14.88 and its 200 day moving average is $14.01. The firm has a market cap of $567.62 million, a price-to-earnings ratio of 26.90 and a beta of 0.89.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. The business had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The company’s revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.21 EPS. On average, analysts predict that Meridian Bioscience will post $0.67 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, August 17th. Stockholders of record on Monday, August 7th will be given a $0.125 dividend. The ex-dividend date of this dividend is Thursday, August 3rd. This represents a $0.50 annualized dividend and a dividend yield of 3.72%. Meridian Bioscience’s dividend payout ratio is 98.04%.

Several large investors have recently bought and sold shares of VIVO. Barrow Hanley Mewhinney & Strauss LLC bought a new stake in Meridian Bioscience during the first quarter valued at approximately $105,000. State of Alaska Department of Revenue boosted its stake in Meridian Bioscience by 77.5% in the second quarter. State of Alaska Department of Revenue now owns 8,273 shares of the company’s stock valued at $130,000 after buying an additional 3,613 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Meridian Bioscience by 12.5% in the first quarter. BNP Paribas Arbitrage SA now owns 8,633 shares of the company’s stock valued at $119,000 after buying an additional 960 shares in the last quarter. Mason Street Advisors LLC boosted its stake in Meridian Bioscience by 7.2% in the first quarter. Mason Street Advisors LLC now owns 9,868 shares of the company’s stock valued at $136,000 after buying an additional 667 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan boosted its stake in Meridian Bioscience by 3.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock valued at $157,000 after buying an additional 370 shares in the last quarter. 85.83% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Meridian Bioscience Inc. (NASDAQ:VIVO) Receives Average Recommendation of “Hold” from Brokerages” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/2801803/meridian-bioscience-inc-nasdaqvivo-receives-average-recommendation-of-hold-from-brokerages.html.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.